Race in a Bottle

Description:

Approved by the FDA in 2005 as the first drug with a race-specific indication on its label, BiDil was touted as a pathbreaking therapy to treat heart failure in black patients. Kahn reveals that, at the most basic level, BiDil became racial through legal maneuvering and commercial pressure as much as through medical understandings of how the drug worked. He examines the legal and calls for a more reasoned approach to using race in biomedical research and practice.

subjects: Public health, united states,  Chemotherapy,  Development,  Pharmaceutical industry,  Health and race,  Hydralazine,  Social aspects,  United States,  Pharmacogenetics,  Medical care,  African Americans,  History,  African americans, medical care,  Political aspects,  Therapeutic use,  Heart Failure,  Drug therapy,  Ethnology,  Isosorbide Dinitrate